Special Issue "Therapeutic Approaches for Myeloproliferative Neoplasms"
Deadline for manuscript submissions: 30 April 2024 | Viewed by 946
Interests: chronic myeloid leukemia; Ph-negative myeloproliferative disorders; MDS; AML; APL
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell myeloid neoplasms that are characterized by the proliferation and preserved differentiation of myeloid cell lineages. Excluding BCR-ABL1-positive chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) are the most frequent MPNs.
Constitutive activation of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT) signaling pathway due to acquired somatic mutations in the JAK2, calreticulin or MPL genes may drive the course of MPNs. These mutations seem to confer the advantage of survival and proliferation to myeloid hematopoietic cells independently of stimulatory signals, leading to clonal expansion of myeloid progenitors and mature cells.
Traditional treatment approaches for PV and ET focus on the prevention of thrombotic events with aspirin along with antiproliferative agents. Treatment strategies for MF are driven by clinical presentations such as anemia and/or splenomegaly. In the last decade, improvement in the therapeutic approaches for MPN have been developed, in particular in PV and MF, with different new drugs on the horizon that will completely change the therapeutic algorithms for these diseases.
In this Special Issue, we aim to collect studies and reviews about the therapeutic landscape of MPNs, with a particular focus on new treatments.
Dr. Massimo Breccia
Dr. Francesca Palandri
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- JAK2 inhibitors
- overall survival
- new treatments
- myeloproliferative neoplasms